

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>A61K 38/18</b>		A1	(11) International Publication Number: <b>WO 96/14081</b> (43) International Publication Date: <b>17 May 1996 (17.05.96)</b>
(21) International Application Number: <b>PCT/NL95/00370</b>		(81) Designated States: AU, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, JP, KR, LT, LV, MD, MX, NO, NZ, PL, RU, SI, SK, UA, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(22) International Filing Date: <b>26 October 1995 (26.10.95)</b>			
(30) Priority Data: 94203205.3 3 November 1994 (03.11.94) EP (34) Countries for which the regional or international application was filed: AT et al.		Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(71) Applicant (for all designated States except US): BOEHRINGER MANNHEIM GMBH [DE/DE]; Sandhofer Strasse 116, D-68298 Mannheim (DE).			
(72) Inventor; and			
(75) Inventor/Applicant (for US only): SWAAK, Anthonius, Josef, Gerardus [NL/NL]; Kralingseweg 322, NL-3066 RB Rotterdam (NL).			
(74) Agent: SMULDERS, Th., A., H., J.; Vereenigde Octrooibureaux, Nieuwe Parklaan 97, NL-2587 BN The Hague (NL).			

(54) Title: USE OF ERYTHROPOIETIN IN THE TREATMENT OF RHEUMATOID ARTHRITIS

(57) Abstract

A novel use of the known protein Erythropoietin (EPO) and/or a derivative and/or a fragment thereof is disclosed. EPO is used as a pharmaceutical for the treatment of chronic inflammations. A particularly beneficial result is seen in patients suffering from rheumatoid arthritis (RA). Significant effects are seen in clinical variables such as morning stiffness, swollen joints, and the like.